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Abstract
BRCA1 and BRCA2 mutations exhibit variable penetrance that is
likely to be accounted for, in part, by other genetic factors among
carriers. However, studies aimed at identifying these factors have
been limited in size and statistical power, and have yet to identify
any convincingly validated modifiers of the BRCA1 and BRCA2
phenotype. To generate sufficient statistical power to identify
modifier genes, the Consortium of Investigators of Modifiers of
BRCA1 and  BRCA2 (CIMBA) has been established. CIMBA
contains about 30 affiliated groups who together have collected
DNA and clinical data from approximately 10,000 BRCA1 and
5,000 BRCA2 mutation carriers. Initial efforts by CIMBA to identify
modifiers of breast cancer risk for BRCA1 and BRCA2 mutation
carriers have focused on validation of common genetic variants
previously associated with risk in smaller studies of carriers or
unselected breast cancers. Future studies will involve replication of
findings from pathway-based and genome-wide association
studies in both unselected and familial breast cancer. The
identification of genetic modifiers of breast cancer risk for BRCA1
and  BRCA2 mutation carriers will lead to an improved
understanding of breast cancer and may prove useful for the
determination of individualized risk of cancer amongst carriers.
The search for genetic modifiers of BRCA1
and BRCA2
Female carriers of deleterious BRCA1 and BRCA2 mutations
are predisposed to high lifetime risks of breast and ovarian
cancer. Initial estimates indicated that around 80% of carriers
of mutations in BRCA1 and  BRCA2 from multiple-case
families would develop breast cancer by age 70 [1,2], and
genetic counseling is usually carried out on the assumption
that penetrance estimates apply to all women. However, a
later pooled analysis from population-based studies
estimated an average risk by age 70 in this context of 66% in
BRCA1 carriers and 45% in BRCA2 carriers [3]. It has also
been reported that cancer risks vary by the age at diagnosis
and the type of cancer in the index case [3,4]. Such
observations are consistent with the more plausible
hypothesis that cancer risks in mutation carriers are modified
by genetic factors or other risk factors that cluster in families.
Segregation analysis has also demonstrated that models that
allow for other genes to have a modifying effect on the breast
cancer risks conferred by BRCA1 and BRCA2 mutations fit
significantly better than models without a modifying
component [5]. Further evidence for genetic modifiers arises
from studies of risk factors that are themselves influenced by
genetic factors. For example, mammographic density that has
a strong genetic component [6] has been recently shown in
one study to modify the breast cancer risks in BRCA1 and
BRCA2 mutation carriers [7].
Although there has been considerable interest in finding
genetic modifiers of cancer risk in BRCA1 and  BRCA2
mutation carriers, the number of published studies is still fairly
modest and has focused around genes involved in a limited
number of pathways: detoxification of environmental carcino-
gens, DNA repair and steroidogenesis. Several studies have
evaluated the CAG repeat length polymorphism in the
androgen receptor (AR) gene as a modifier of breast cancer
risk among mutation carriers. However, the data from different
studies are contradictory and no firm conclusions can be
drawn as to the magnitude of such an effect, if any [8-11].
Many studies have also evaluated a repeat length poly-
morphism in AIB1 as a modifier of risk among BRCA1 or
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BRCA2 mutation carriers. Although an effect of high numbers
of repeats on cancer risk in carriers was first reported by
Rebbeck and colleagues [12], three large subsequent
studies failed to replicate this result [13-15]. RAD51 currently
provides the most convincing evidence for the existence of a
modifier gene, at least for BRCA2 mutation carriers. Levy-
Lahad and colleagues [16] first reported that the -135G>C
single nucleotide polymorphism (SNP) in the 5′ untranslated
region of RAD51 modified the breast cancer risk in BRCA2
carriers and this finding has been substantiated by others
[17,18]. The function of the -135G>C SNP in RAD51 is not
clear, but it could affect mRNA stability or translational
efficiency.
Choosing candidate SNPs or genes to evaluate as modifiers
of BRCA1 and BRCA2 suffers from the same problem faced
by all candidate-based genetic association studies, namely
the poor understanding of the relevant pathways and hence
the small a priori likelihood that any of them are true modifiers
[19]. These issues may be overcome in the future through the
identification of candidate genomic regions associated with
breast cancer risk by linkage analyses [20], or more plausibly
by the identification of candidate SNPs by adequately
powered genome-wide association studies [21]. In addition,
the publication of convincingly validated SNPs associated
with breast cancer in the general population [22] will provide
some new candidates to test as modifiers of breast cancer
risk among BRCA1 or BRCA2 mutation carriers. However,
since SNPs associated with breast cancer in the general
population may not act in the same way among BRCA1 and
BRCA2 mutation carriers, pathway-based and perhaps
genome-wide association studies in BRCA1 and  BRCA2
carriers are also needed.
Consortium of Investigators of Modifiers of
BRCA1 and BRCA2 (CIMBA)
A number of large studies and consortia have been
established that aim to identify genetic modifiers of cancer
risk in BRCA1 and  BRCA2 mutation carriers, including
Modifiers and Genetics in Cancer (MAGIC), Epidemiological
study of BRCA1 and BRCA2 mutation carriers (EMBRACE),
Genetic Modifiers of cancer risk in BRCA1/2 mutation
carriers (GEMO), the Kathleen Cuningham Consortium for
Research into Familial Breast Cancer (kConFab), the German
Consortium for Hereditary Breast and Ovarian Cancer
(GCHBOC) and the Breast Cooperative Family Registry
(Breast-CFR). However, with current sample sizes of less
than 1,500 carriers, none of these groups have adequate
power to identify genetic modifiers with confidence. To
address this problem, a ‘consortium of consortia’, the
Consortium of Investigators of Modifiers of BRCA1 and
BRCA2 (CIMBA), was established in 2005 (see Additional
file 1 for a list of current contributors). The operating
principles of CIMBA are: CIMBA is open to any group that
can contribute genotypic and basic phenotypic and
epidemiological risk factor data from at least 100 female
BRCA1 and  BRCA2 mutation carriers with or without a
cancer diagnosis - groups with smaller collections of carriers
are encouraged to participate through partnership with a
larger group; panels of SNPs for genotyping are selected at
face-to-face meetings every six months; only SNPs that show
significant associations (arbitrarily set at p < 0.01) with breast
cancer risk in carriers, either in the published literature or in
data from a member group, or are convincingly identified as
associated with breast cancer in the general population, are
considered; each group is free to participate, or not, in any
round of genotyping; genotyping quality control standards
must be followed (>2% duplicates, call rates >95%, no-
template controls on every plate and randomized arrange-
ment of affected and unaffected carriers for genotyping); all
epidemiological risk factor data and genotyping data from
carriers are submitted to the CIMBA data coordinating centre
at the University of Cambridge; and genotyping data from
participating centers are pooled for analysis. There are
currently about 30 groups from North America, Europe and
Australia who plan to contribute to some or all of the
collaborative CIMBA projects, and collectively they have DNA
and minimum required clinical and epidemiological data from
more than 10,000 BRCA1 and 5,000 BRCA2 carriers.
Statistical considerations
Most association studies are case-control studies, in which
genotype frequencies in a series of cases are compared with
those in series of controls. The analysis of BRCA1 and
BRCA2 modifiers is potentially more complex, because a
high proportion of carriers become affected. Thus, modifiers
would be expected to influence not just whether a carrier
became affected but also the age at diagnosis. More
powerful analyses can, therefore, be conducted by treating
breast cancer as a survival (age at onset) rather than a simple
binary endpoint. An additional problem, however, is
introduced by the fact that mutation carriers are mainly
ascertained through cancer genetics clinics. In these
settings, the first tested individual in a family is usually
someone diagnosed with cancer at a relatively young age.
Such study designs tend, therefore, to lead to an over-
sampling of affected individuals and standard analytical
methods like Cox regression may lead to biased estimates of
the risk ratios [5]. CIMBA aims to address this potential bias
by using standard analytical methods, such as weighted Cox
regression, or by analyzing the data within a retrospective
likelihood framework [5]. In addition, analyses restricted to
incident cases, defined as carriers diagnosed with cancer no
more than five years prior to ascertainment, are applied to
account in part for ascertainment and possible survival bias.
One of the aims of CIMBA is also to further develop the
statistical methodology used to analyze such data. Among
BRCA1 mutation carriers and at a threshold of p < 0.0001,
CIMBA currently has a power of over 80% to detect
polymorphisms with minor allele frequencies greater than
10% that confer risk ratios in excess of 1.2 (Table 1). The
power is somewhat lower among the current sample ofPage 3 of 4
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BRCA2 mutation carriers. However, it is still far greater than
the power that be achieved by each study individually - at a
minor allele frequency of 20% and risk ratio of 1.2, the
corresponding power would be <5% for a sample size of
approximately 1,000 carriers. Moreover, most of the
participating CIMBA centers are actively recruiting carriers,
and larger sample sizes are expected in the future.
Conclusions
The identification of convincingly validated modifiers of breast
cancer risk for BRCA1 and  BRCA2 mutation carriers will
help to understand the biology of hereditary breast tumors
and, in the case of BRCA1-mutation-associated risk
modifiers, will also provide candidate low penetrance genes
for ‘sporadic’ basal cell breast cancers because of their
similarity to BRCA1-related breast tumors [23,24]. In the
long term it might be possible to include information on
genetic modifiers in risk prediction models, to give
individualized advice to mutation carriers on individual breast
cancer risks, and to have sufficient power to evaluate the risk
of other cancers in BRCA1 and BRCA2 mutation carriers.
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